Open Access

Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells

  • Authors:
    • Jun Lu
    • Xiaowu Jenifer Wu
    • Amira Hassouna
    • Kelvin Sheng Wang
    • Yan Li
    • Tao Feng
    • Yu Zhao
    • Minfeng Jin
    • Baohong Zhang
    • Tianlei Ying
    • Jinyao Li
    • Lufeng Cheng
    • Johnson Liu
    • Yue Huang
  • View Affiliations

  • Published online on: June 1, 2023     https://doi.org/10.3892/br.2023.1629
  • Article Number: 46
  • Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gemcitabine is a chemotherapeutic agent for pancreatic cancer treatment. It has also been demonstrated to inhibit human pancreatic cancer cell lines, MIA PaCa‑2 and PANC‑1. The aim of the present study was to investigate the suppressive effect of fucoxanthin, a marine carotenoid, in combination with gemcitabine on pancreatic cancer cells. MTT assays and cell cycle analysis using flow cytometry were performed to study the mechanism of action. The results revealed that combining a low dose of fucoxanthin with gemcitabine enhanced the cell viability of human embryonic kidney cells, 293, while a high dose of fucoxanthin enhanced the inhibitory effect of gemcitabine on the cell viability of this cell line. In addition, the enhanced effect of fucoxanthin on the inhibitory effect of gemcitabine on PANC‑1 cells was significant (P<0.01). Fucoxanthin combined with gemcitabine also exerted significant enhancement of the anti‑proliferation effect in MIA PaCa‑2 cells in a concentration dependent manner (P<0.05), compared with gemcitabine treatment alone. In conclusion, fucoxanthin improved the cytotoxicity of gemcitabine on human pancreatic cancer cells at concentrations that were not cytotoxic to non‑cancer cells. Thus, fucoxanthin has the potential to be used as an adjunct in pancreatic cancer treatment.
View Figures
View References

Related Articles

Journal Cover

July-2023
Volume 19 Issue 1

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lu J, Wu XJ, Hassouna A, Wang KS, Li Y, Feng T, Zhao Y, Jin M, Zhang B, Ying T, Ying T, et al: Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells. Biomed Rep 19: 46, 2023
APA
Lu, J., Wu, X.J., Hassouna, A., Wang, K.S., Li, Y., Feng, T. ... Huang, Y. (2023). Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells. Biomedical Reports, 19, 46. https://doi.org/10.3892/br.2023.1629
MLA
Lu, J., Wu, X. J., Hassouna, A., Wang, K. S., Li, Y., Feng, T., Zhao, Y., Jin, M., Zhang, B., Ying, T., Li, J., Cheng, L., Liu, J., Huang, Y."Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells". Biomedical Reports 19.1 (2023): 46.
Chicago
Lu, J., Wu, X. J., Hassouna, A., Wang, K. S., Li, Y., Feng, T., Zhao, Y., Jin, M., Zhang, B., Ying, T., Li, J., Cheng, L., Liu, J., Huang, Y."Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells". Biomedical Reports 19, no. 1 (2023): 46. https://doi.org/10.3892/br.2023.1629